Please try another search
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company’s lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It also develops Bemcentinib, which is in preclinical trial to treat acute respiratory distress syndrome; Tilvestamab (BGB149), anti-AXL monoclonal antibody, which in phase 1 clinical trial for the treatment of ovarian cancer; and Mipasetamab Uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. BerGenBio ASA was incorporated in 2007 and is based in Bergen, Norway.
Name | Age | Since | Title |
---|---|---|---|
Debra Barker | 61 | 2019 | Independent Non-Executive Director |
Sveinung Hole | - | 2010 | Independent Non-Executive Director |
Sally L. Bennett | - | 2020 | Independent Non-Executive Director |
Solange Peters | - | 2023 | Member Scientific Advisory Board |
Shu Kam Mok | 62 | 2023 | Member of Scientific Advisory Board |
Enriqueta Felip | - | 2023 | Member of Scientific Advisory Board |
John Heymach | - | 2023 | Member of Scientific Advisory Board |
Anders Lennart Tullgren | 62 | 2022 | Independent Chairman of the Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review